DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for expected IND submission, or ...
Schrödinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to focus on advancing its ...
The nearly 30-year tale of secalosides A and B began in 1997, when natural product chemists identified them as components of rye pollen extract. Although the compounds were inactive in lab tests with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback